Osteocytes, the most abundant cells in bone, are essential for the functioning of the skeleton. Far from being inactive quiescent cells buried in mineralized tissue (FIG. 1) , osteocytes coordinate bone acquisition during growth and the maintenance of a healthy skeletal frame for locomotion and the protection of essential organs 1 . Osteocytes orchestrate the work of osteoblasts that form bone and osteoclasts that resorb bone by producing and secreting factors that enable the skeleton to adapt to mechanical needs and hormonal changes 2 . Osteocytes contribute to the endocrine functions of bone by secret ing hormones that affect other tissues and regulate mineral homeostasis and haematopoiesis, processes that are essential for organismal life 1,2 . In this Review, we revisit the early observations and new evidence that support a central role for osteocytes in bone homeostasis. We describe the molecular and functional signature of osteocytes, and the mechanisms by which osteocytes integrate environmental cues provided by the mechan ical and hormonal stimuli to which bone is subjected. We further discuss the potential of osteocytic signalling pathways as therapeutic targets to improve bone health and highlight the importance of future research exploring holistic approaches towards musculoskeletal integrity.
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Osteocytes and bone homeostasis
The central role of osteocytes in bone homeostasis has long been envisioned by pioneers in the field, who pro posed potential mechanisms by which these cells could contribute to the functions of the skeleton, well before such mechanisms were identified. Gastone Marotti and colleagues found by microscopic examination of human bone that osteocytes within lacunae have multiple cyto plasmic projections that reach neighbouring osteocytes and cells on bone surfaces 3 . Marotti proposed that osteo cytes are key participants in this cellular network in which cells, connected via gap junctions, are able to sense mechanical and biochemical signals 4 . As osteo cytes have longer and more abundant dendrites facing the bone surface than the mineralized bone, and the number of osteocytic dendrites in contact with osteo blasts is inversely proportional to osteoblast size (and thus activity), Marotti and colleagues proposed that osteo cytes send inhibitor signals to osteoblasts to slow bone formation 4 . On the basis of this theory, R. Bruce Martin developed a mathematical model predicting that dur ing the refilling of resorption cavities an initial increase in bone formation occurs, followed by a reduction in osteo blast activity as osteocytes mature 5 . This model also predicts that the osteoblasts most affected by osteo cytic inhibitory signals have a higher probability of being buried within the matrix still being synthesized by neigh bouring osteoblasts, thus becoming the next population of osteocytes. Today, the importance of the osteocyte network and the mechanisms and messengers by which osteocytes control not only bone formation but also bone resorption and haematopoiesis, are recognized and some of the molecular mediators have been identified. , and devel oped the 'mechanostat' theory, which proposes that the magnitude of the mechanical stimulation applied to bone dictates whether bone will be increased (by increasing bone formation) or decreased (by increasing bone resorp tion) 8 . In this model, osteocytes sense the load imposed on bone and respond by signalling to osteoblasts and osteo clasts to adapt to mechanical changes 9 . We now know that one of the osteocytederived molecules involved in bone adaptation is sclerostin (encoded by SOST) 10, 11 . Seminal work by A. Michael Parfitt in the 1970s pos tulated that osteocytes are involved in the response of the skeleton to parathyroid hormone (PTH) 12 . On the basis of the rapid timing of hypercalcaemic responses to PTH, the fact that new protein synthesis is not required, and that calcium is released into the circulation at two different rates, Parfitt concluded that osteocytes control the rapid release of calcium, whereas osteoclasts and resorption determine the later phase of PTHinduced calcium release from bone into the circulation. Indeed, later studies using genetically modified mice have demonstrated profound skeletal effects of activation of the PTH receptor in osteo cytes [13] [14] [15] [16] and a defective response to PTH in mice lacking this receptor in osteocytes [17] [18] [19] . These studies support and extend Parfitt's concept that osteocytes are target cells of PTH action. Furthermore, mice lacking the PTH receptor in osteocytes lose less bone with lactation than controls, a condition in which calcium release from the skeleton to the blood induced by parathyroid hormonerelated protein (PTHrP; the other ligand of the PTH receptor) is required for milk production in the mammary glands 20 . In addition, the characteristic increase in osteocyte lacu nar size observed in lactating wildtype mice is not found in mice lacking the PTH receptor in osteocytes, which suggests that removal of perilacunar bone by osteocytes is a source of calcium and contributes to bone loss. The process of perilacunar remodelling, previously termed osteocytic osteolysis by Leonard Belanger 21 , is achieved by osteocytes expressing genes that are usually expressed in osteoclasts during bone resorption. These genes encode for proteins that decrease extracellular pH (such as carbonic anhydrases and ATPases), degrade the extracell ular matrix (such as collagenase 3; also known as matrix metalloproteinase 13 (MMP13) and cathepsin K), or dissolve the mineral (such as tartrateresistant acid phosphatase type 5; also known as TRAP).
The molecular mechanisms by which osteocytes accomplish the functions postulated by the pioneers of the field are, thus, being unravelled, and current research will continue to increase our knowledge of osteocyte biology and pathophysiology.
Osteocyte signature Genes and function An estimated 5-20% of osteoblasts present on the bone surface become surrounded by the matrix proteins they produce, and differentiate into osteocytes 22, 23 . The mech anism by which some osteoblasts and not others undergo this process is uncertain. Nevertheless, this transition is characterized by alterations in gene expression and is accompanied by morphological and functional cell changes. The highly secretory osteoblasts are character ized by their cuboidal shape and large nucleus located close to the cell basal membrane, enlarged Golgi apparatus on the nuclear apical surface, and extensive endoplasmic reticulum. During osteocytogenesis, the number of orga nelles markedly decreases and the nuclear to cytoplasm volume ratio increases as cells acquire a starlike morphol ogy (FIG. 1) . The long cytoplasmic processes of osteocytes run through canaliculi burrowed in mineralized bone and touch neighbouring osteocytes, cells on the bone surface, and endothelial cells of blood vessels. This extensive lacunar-canalicular system is maintained by the ability of osteocytes themselves to remodel their surrounding space, as demonstrated by calcification of the lacuna and reduced numbers of canaliculi when osteocytes are lost by apoptosis. The osteocyte lacunar-canalicular system also distributes molecules secreted by osteocytes among all the cells of bone and the bone marrow.
Genes that are regulated during osteocyte develop ment and maturation can be grouped, based on their function, into four main categories: genes related to dendritic morphology and canaliculi formation that facilitate cell embedding in the bone matrix; genes related to phosphate metabolism and matrix minerali zation; genes that regulate bone formation; and genes that regulate bone resorption (FIG. 2) .
Formation and maintenance of the osteocytic network.
The transition from osteoblasts to osteocytes occurs when the cells become surrounded first by unmineral ized matrix or osteoid and, later, by mineralized bone matrix. Several proteins have been identified as medi ators of the development of dendrites by dictating the formation of osteocytic projections or, indirectly, by con trolling mineralization and matrix degradation and thus the proper formation of the lacunar-canaliculi system. Podoplanin (also known as transmembrane glyco protein E11, OTS8, glycoprotein 38 and T1α) was orig inally described in osteoblastic cells treated with phorbol 24, 25 , and subsequently cloned from other tissues. Podoplanin is expressed in dendritic cells of the kidney, lung, brain and skin 26, 27 . In bone, podoplanin is expressed in newly embedded osteocytes, but not in mature osteo cytes deep within the bone matrix or in osteoblasts on the bone surface, which indicates that podoplanin is a marker of early osteocyte differentiation 28 . Podoplanin expression is required for dendrite elongation induced by mechanical loading in vitro and is increased by mechanical stimula tion both in vitro and in vivo, which suggests that these signals control osteocytogenesis.
Podoplanin binds to CD44, a molecule also expressed in neuronal dendrites 29 , and expression of either mole cule has been associated with osteocytic dendrite branch ing 30, 31 . Osteocytic dendrites also contain αactinin and fimbrin, actinbundling proteins required for cytoskeletal organization of osteocytes isolated from chicken 32, 33 . Remarkably, mutations in PLS3 (encoding plastin3; the human homologue of fimbrin) leads to Xlinked osteo porosis with fractures 34 , which suggests an association between deficient dendrite formation and bone fragility.
Dentin matrix acidic phosphoprotein 1 (also known as DMP1 and encoded by DMP1) is expressed in mature osteoblasts and its expression increases as osteoblasts differentiate towards osteocytes 35 . DMP1 is required for proper osteocyte maturation. This is evidenced by abnormally elevated expression of osteoblastic and early osteocytic genes (such as those encoding alkaline phosphatase, collagen type 1 and podoplanin) and low expression of sclerostin (a marker of mature osteocytes) in deeply embedded osteocytes in mice lacking DMP1 (REF. 36 ). Furthermore, mineralization is defective in these . As with DMP1, the expression of MMPs also increases as osteoblasts differentiate into osteocytes. The function of MMPs in osteocytogenesis might be related to their ability to cleave collagen in the matrix surrounding osteocytes, enabling the formation of canaliculi through which osteo cytes extend cytoplasmic projections. Consistent with this notion, mice lacking MMP14 exhibit reduced or absent osteocytic processes 39 . Furthermore, the ability of colla gen to be degraded by MMP13 is required to maintain osteocyte viability, as demonstrated by increased osteocyte apoptosis in mice expressing a mutated nondegradable collagen 1 (REF. 40 ).
A protein crucial for the functionality of the osteocyte network is gap junction α1 protein (commonly known as connexin 43 (CX43)), the most abundant member of the connexin family of proteins expressed in osteocytes 41 . CX43 forms gap junction channels between cells partici pating in celltocell communication within the osteocyte network; CX43 also forms hemichannels connecting cells with the extracellular milieu. Deletion of the CX43 gene (GJA1) from osteocytes in mice decreases osteocyte viability and induces changes in the geometry of long bones, producing bones with features resembling those from old mice or humans [42] [43] [44] . These features include an increased number of apoptotic osteocytes and empty lacunae, a bone marrow cavity that is enlarged by exaggerated endosteal resorption, and bones of increased diameter due to increased periosteal bone apposition. These effects of CX43 deletion are intrinsic to osteocytes, as knockdown of the gene in vitro results in cells that die spontaneously and exhibit an increased receptor activator of nuclear factor κB ligand (RANKL):osteoprotegerin (OPG) ratio and the ability to support osteoclast formation 44, 45 . Furthermore, osteo clasts are found on bone surfaces adjacent to areas where apoptotic osteocytes accumulate in CX43 knockout mice, which suggests that signals released by dying osteocytes are required to target osteoclast recruitment. CX43 expression in osteoblasts and osteocytes is also required for cell survival induced by bisphosphonates or PTH, as well as for full bone anabolism in response to PTH [46] [47] [48] [49] . CX43 is also involved in the response of osteocytes to mechanical signals. In vitro studies have demonstrated that mechanical stimulation of osteocytes opens CX43 hemi channels and induces prostaglandin E 2 (PGE 2 ) release in a CX43dependent manner, which in turn promotes osteo cyte survival 41, 50 . These findings suggested that CX43 is critical for mechanotransduction; however, paradoxically, CX43 restrains the response of bone to mechanical stimu lation in vivo, as deletion of the CX43 gene from osteocytes enhances the anabolic response of bone to loading [51] [52] [53] .
Phosphate metabolism and matrix mineralization.
A feature of osteocyte differentiation is the increase in expression of genes related to phosphate metabo lism and matrix mineralization 35 . These genes encode for a number of factors including, fibroblast growth factor 23 (FGF23), members of the small integrinbinding ligand, Nlinked glycoprotein (SIBLING) family of proteins such as DMP1 and matrix extracellular phos phoglycoprotein (MEPE), phosphateregulating neutral endopeptidase (PHEX), which has homology with genes encoding endopeptidases on the X chromosome, and fetuinA 35, 54 (FIGS 2,3).
FGF23 is produced by osteocytes and regulates phos phate metabolism by acting in the kidney. FGF23 binds to FGF receptors and the Klotho coreceptor in the renal proximal tubule, which leads to inhibition of renal phos phate reabsorption 55 . Deletion of Fgf23 in mice leads to hyperphosphataemia, decreased BMD, deficient bone formation and accumulation of unmineralized osteoid 56 . FGF23 might also act in an autocrine and/or paracrine manner in osteocytes and other bone cells, as receptors for FGF23 (that is, FGF receptor 1 (FGFR1) and Klotho) are also expressed in these cells and could mediate FGF23 functions dependent as well as independent of its coreceptor Klotho 15, 57 . Deletion of the renal Na/Pi cotransporter NaPi2a, thus, reverses the hyperphos phataemia but not the defective mineralization of bone in mice lacking FGF23 (REF. 57 ), which suggests a direct effect of FGF23 on bone cells. Additionally, Klotho is expressed in bone cells in vivo in long bones and calvaria at both the protein and mRNA levels, as well as in isolated osteo blasts and osteocytes 15 . Furthermore, levels of FGF23 are increased in mice with active PTH receptor signalling in osteocytes (designated DMP1caPTHR1 mice), and this leads to increased levels of FGFR1, polypeptide Nacetylg alactosaminyltransferase 3 (GalNAcT3), as well as down stream targets of FGF23 signalling in osteocytes, which supports a direct effect of FGF23 in bone 15 .
Other osteocyteproduced molecules regulate FGF23 expression and/or function, and therefore indirectly affect phosphate homeostasis. For example, inactivating mutations in DMP1 or PHEX in humans result in high levels of FGF23 and hypophosphataemia 58 . As reducing levels of FGF23 and correcting the hypophosphataemia only partially rescues the osteomalacia, the defective bone mineralization observed in these diseases probably results from a combination of FGF23mediated effects in the kidney and direct action of DMP1 and PHEX in bone. Furthermore, studies in animal models and humans show that altered levels of FGF23, PHEX, DMP1 and MEPE are associated with impaired glucose metabolism, probably as a result of decreasing levels of undercarboxylated osteo calcin 59 . This group of osteocytederived proteins, thus, directly or indirectly modulate the homeostasis of bone, kidney and other tissues and/or organs.
As discussed earlier in the text, DMP1 is required for proper bone mineralization, whereas MEPE is a mineralization inhibitor whose deletion from the mouse genome results in increased BMD 60 
(FIGS 2,3).
Expression of DMP1 and MEPE is upregulated by loading and these proteins might be responsible for the local effects of mechanical stimulation in the matrix surrounding osteo cytes 61 . Enzymatic degradation of MEPE generates an acidic serine aspartaterich MEPE associated (ASARM) peptide that blocks mineralization in vitro and in vivo 62 . PHEX is a metalloendopeptidase that binds to MEPE and its ASARM peptide. Deletion of Phex in mice results in osteomalacia and an abnor mal osteocytic lacuna-canalicular system 63 . The liver protein fetuinA, an inhibitor of bone mineralization and ectopic calcification, is also expressed in bone and is enriched in osteocytes compared with osteoblasts 54 . Osteocytes control bone mineralization and levels of phosphate in the circulation by producing proteins that act locally on bone cells or as endocrine hormones in the kidney. A complex interaction exists among these proteins that involves positive and negative feed-back, which maintains phosphate levels tightly regulated. DMP-1, dentin matrix acidic phosphoprotein 1; FGF23, fibroblast growth factor 23; MEPE, matrix extracellular phosphoglycoprotein; PHEX, phosphate-regulating neutral endopeptidase.
Canonical Wnt signalling
Signalling pathway that results from activation of the LRP5/6 and frizzled co-receptors, leading to accumulation of β-catenin, its nuclear translocation and transcription of specific target genes that affect bone formation and resorption.
FetuinA might be involved in the formation of cellular processes by slowing calcification of the matrix that sur rounds developing osteocytes. The regulation of phosphate metabolism seems to result from highly interrelated functions of these osteo cytic proteins, as changes in the expression level of one of these molecules alters the expression of others, constituting a cascade that ultimately regulates bone mineralization (FIG. 3) . Some examples of this interplay are the high levels of FGF23 found in humans who lack functional DMP1 and PHEX 58 , the decrease in levels of active FGF23 due to PHEX binding to DMP1, the reversal of hypophosphataemia in PHEXdeficient mice by FGF23 deletion 56 , and the increase in fetuinA expression in osteocytes by an autocrine function of FGF23 (REF. 54 ).
Altered expression of some of the osteocytic genes described earlier in the text leads to disorders of phos phate homeostasis in humans 58 . Excess production of FGF23 or gainoffunction mutations in this hormone results in hypophosphataemia, renal phosphate wast ing, low levels of vitamin D 3 and vitamin Dresistant rickets (a condition known as autosomal dominant hypophosphataemic rickets). Increased FGF23 is found in chronic kidney disease (CKD) and is associated with an increased risk of cardiovascular disease and death. The high levels of FGF23 found in patients with late stage CKD are partially due to increased levels of PTH, as evidenced by the reduction in serum FGF23 follow ing parathyroidectomy in animal models and patients with CKD. Increased levels of FGF23 were found in the circulation of a patient with Jansen's metaphyseal chon drodysplasia, which is characterized by expression of a constitutively active PTH receptor 64 . Similarly, mice expressing the same PTH receptor mutant in osteocytes exhibit increased expression of FGF23 (REF. 15 ). These findings demonstrate that some of the actions of PTH in controlling mineral metabolism are mediated through regulation of osteocytederived FGF23. Other forms of hypophosphataemia resulting from changes in osteo cytic genes are Xlinked hypophosphataemic rickets due to inactivating mutations in PHEX and autosomal recessive hypophosphataemic rickets due to inactivating mutations in DMP1 (REF. 58 ).
Regulation of bone formation. One of the most impor tant events of the past 20 years that advanced our under standing of skeletal biology was the discovery of the role of Wnt-βcatenin signalling in bone 65 . The socalled canonical Wnt signalling pathway controls the fate of mes enchymal stem cells (MSCs) and their differentiation into various cell lineages. Canonical Wnt signalling restrains chondrogenic and adipogenic differentiation while enhancing osteoblastic differentiation from MSCs. In addition, Wnt-βcatenin signalling promotes osteoblast maturation, survival of osteoblasts and osteocytes, and inhibition of osteoclastogenesis, indirectly via increasing the expression of OPG in osteoblasts and osteocytes.
Osteocytes have a critical role in the regulation of this signalling pathway both as targets of Wnt ligands and as producers of molecules that modulate their action.
Wnt-βcatenin signalling is activated by binding of Wnt proteins to a receptor complex composed of frizzled receptors and coreceptors of the low density lipoprotein receptorrelated protein (LRP) family, such as LRP5 and LRP6. This event stabilizes βcatenin, induces its translo cation to the nucleus and activates gene transcription 65 . Activation of this pathway is critical for bone acquisition and maintenance through increased bone formation and decreased resorption.
Dickkopfrelated protein 1 (DKK1) is a Wnt antago nist expressed in osteoblasts and at higher levels in osteo cytes 66 . DKK1 binds to LRP5 and LRP6 preventing the binding of Wnt ligands. Mice overexpressing DKK1 in osteoblastic cells exhibit decreased bone formation and low bone mass, consistent with the stimulatory role of the Wnt-βcatenin pathway on bone formation 67 (FIG. 4) .
Another Wnt inhibitor, secreted frizzledrelated protein 1 (SFRP1) is expressed in early osteocytes and its levels decrease as osteocytes mature 68 . Consistent with the role of SFRP1 as an inhibitor of anabolic Wnt-βcatenin sig nalling, deletion of the gene encoding it from the mouse genome results in increased bone mass 65 .
Another antagonist of Wnt signalling is sclerostin, which is primarily expressed by mature osteocytes but not by early osteocytes or osteoblasts 69 . Sclerostin binds to the Wnt coreceptors LRP5/LRP6 and antago nizes downstream signalling 70 . Sclerostin also binds to LRP4, another member of the LRP family of proteins, which acts as a chaperone and is required for the inhib itory action of sclerostin on Wnt-βcatenin signalling 71 . Absence of SOST expression or secretion of sclerostin in humans results in sclerosteosis, van Buchem disease or craniodiaphyseal dysplasia, which are inherited con ditions of high bone mass characterized by exaggerated bone formation 65 . Furthermore, inactivating mutations in the Wnt coreceptor LRP5 result in low bone mass (osteoporosis pseudoglioma); conversely, activating mutations in LRP5 lead to high bone mass partially due to decreased binding affinity of the mutated LRP5 for sclerostin. Consistent with the requirement of LRP4 for the inhibitory function of sclerostin, individuals with inactivating mutations in LRP4 exhibit high bone mass. Moreover, deletion of Sost or Lrp4 in mice or neutralizing antibodies against sclerostin or LRP4 reproduce the high bone mass phenotype found in humans lacking scleros tin or LRP4 activity [72] [73] [74] [75] [76] , whereas overexpression of Sost or sclerostin decreases bone mass 11, 14, 77, 78 . Remarkably, osteocytetargeted deletion of Lrp5 or overexpression of high bone mass LRP5 mutants specifically in osteocytes reproduces the low or high bone mass phenotypes exhib ited by mice or humans with the genetic modifications in all cells 79 . This finding suggests that activation of the pathway in osteocytes is sufficient to elicit bone forma tion downstream of LRP5 (REFS 79, 80 ). This conclusion is consistent with findings demonstrating that osteocytes mediate the anabolic actions of canonical Wnt-βcatenin signalling in bone 81 . Osteocalcin, the most abundant noncollagenous pro tein present in bone, is an inhibitor of bone formation, as evidenced by the high bone mass in the absence of defective bone mineralization or bone resorption in mice lacking the osteocalcin gene 82 . Osteocalcin is a marker of osteoblasts. However, in mice osteocalcin is expressed at higher levels in osteocytes than in osteoblasts 83 , and osteo cytes are more abundant than osteoblasts. Osteocytes, as well as osteoblasts, therefore possibly contribute to the pool of osteocalcin in the circulation. However, the main cellular source of this hormone is not known. Studies in mice have shown that, in addition to its role in bone, osteocalcin in its undercarboxylated form can regulate insulin production and/or secretion by pancreatic β cells, insulin sensitivity and glucose uptake in muscle, and fat metabolism 84 . In addition, osteocal cin might regulate testosterone production 85 and brain development and function 86 . However, the extraskeletal role of osteocalcin as a molecule with endocrine prop erties remains controversial and additional studies are required to determine the relevance of the purported extraskeletal functions of osteocalcin in humans both under physiological and pathological conditions. Regulation of bone resorption and the role of osteo cyte apoptosis. Osteocytes produce cytokines that regulate osteoclast formation and survival (FIG. 4) . Osteoclastogenesis involves activation of the receptor activator of nuclear factor κB (RANK) in osteoclast precursors induced by RANKL, which is produced by stromal and/or osteoblastic cells as well as by osteocytes 35 . Osteocytes also secrete the RANKL decoy receptor OPG, which binds RANKL and competes with RANK, thus inhibiting osteoclast differentiation. In studies using genetically modified mice, deletion of Rankl from osteo cytes renders mice osteopetrotic, due to a reduced number of osteoclasts, decreased bone resorption and a progressive increase in bone mass 87, 88 , which suggests that osteocytes are an important source of RANKL in bone.
Macrophage colonystimulating factor (MCSF), produced by bone cells including osteocytes 66 , promotes the proliferation and survival of osteoclast precursors, and is required for osteoclast formation 89 . Similar to mice lacking MCSF in all tissues 90 , mice lacking this factor only in osteocytes exhibit reduced osteoclast numbers and osteopetrosis, which demonstrates that osteocytes are an important source of the cytokine in bone 91 . Osteocytes also express receptors for MCSF 66 , and mice lacking osteocytic MCSF have osteocytes with abnormal morphology, a high prevalence of apoptosis, increased production of reactive oxygen species, and reduced gap junction communications 91 . These findings suggest that osteocytes are not only an important source of MCSF, but also a target cell for this cytokine, which controls osteocyte viability.
The antiosteoclastogenic cytokine OPG is expressed in both osteoblasts and osteocytes, and OPG mRNA expression is more abundant in osteocytes than in osteoblasts isolated by serial digestions of bones from 6weekold mice and at least as abundant in cells from 4monthold mice 92 . Moreover, OPG is a target of canon ical Wnt signalling and mice lacking βcatenin in osteo blasts and/or osteocytes exhibit similarly reduced OPG expression, increased numbers of osteoclasts, and low bone mass [92] [93] [94] . These findings suggest that the regulation of osteocytic OPG by Wnt-βcatenin signalling has an important role in the control of bone resorption.
Osteocyte viability is an important component of the cascade of events that directs osteoclasts to particular bone surfaces, socalled targeted bone remodelling 2, 95, 96 . Accumulation of apoptotic osteocytes in certain areas of bone promotes preosteoclast recruitment, local osteo clast differentiation and increased bone resorption. Although the mechanisms underlying this phenome non are still unclear, osteocyte apoptosis is recognized to temporally and spatially precede osteoclastic resorption. Induction of osteocyte apoptosis by injecting diphthe ria toxin into transgenic mice expressing the diphtheria toxin receptor in osteocytes is sufficient to increase osteo clast numbers and trigger resorption in the vicinity of dead osteocytes 97 . Moreover, osteocyte death is accom panied by increased osteoclast numbers in nearby bone in rodent models of unloading, excessive mechanical forces, or ovariectomy. These findings support the pos sibility that increased osteocyte apoptosis is a generalized mechanism to induce localized bone resorption.
One of the potential mechanisms by which increased osteocyte apoptosis could trigger local bone resorp tion is by increasing RANKL expression in osteocytes located close to dying cells. This notion is supported by the fact that inhibition of apoptosis by administering anti apoptotic bisphosphonates or caspase inhibitors blocks the increase in osteocytic RANKL found in the afore mentioned animal models 2, 95, 96, 98, 99 . Further, deletion of RANKL from osteocytes and mature osteoblasts prevents the decrease in bone mass and the increase in osteoclast number in tailsuspended mice 87 . Moreover, inhibition of osteocyte and/or osteoblast apoptosis with a bisphospho nate that does not affect osteoclasts or with a pan caspase inhibitor prevents the increase in osteocytic RANKL induced by unloading 98 . Notably, the bisphosphonate did not prevent the loss of bone 98 whereas the caspase inhib itor did 99 . Nevertheless, these findings demonstrate a causeandeffect relationship between osteocyte apopto sis and osteocytic RANKL and suggest that, at least under certain unloading conditions, osteocytic RANKL is crucial for osteoclast formation and bone resorption.
In addition to osteocytic genes or pathways that reg ulate either bone formation or bone resorption, genetic manipulations that target osteocytes can simultaneously control both arms of bone remodelling. For example, activation of βcatenin in osteocytes increases bone mass in the context of elevated bone formation and bone resorption, which leads to high levels of bone remod elling with bone gain 81 . This effect contrasts with the finding that activation of βcatenin in osteoblasts and/or osteocytes increases bone mass due to reduced bone resorption, without affecting osteoblast function 94 .
Mechanical and hormonal stimuli in bone
Integration by osteocytes Owing to their strategic location, osteocytes have long been considered the ideal cells to mediate bone adaptation to changes in the mechanical environ ment; extensive evidence accumulated during the past several decades has revealed many mechanisms that are potentially involved in this phenomenon. Changes in mechanical force profoundly affect the viability of osteo cytes. Furthermore, mechanical stimulation alters the expression of osteocytic genes and induces the release of small molecules, which, in turn, regulate the gener ation and function of osteoblasts and osteoclasts, thus affecting bone modelling and remodelling. Osteocytes are also target cells for the action of systemic hormones, which activate similar as well as different pathways than mechanical stimuli (FIG. 5) . Crosstalk between hormo nal and mechanical signalling exists in osteocytes, as demonstrated by modulation of mechanoresponses by systemic hormones or by changes in the expression of hormone receptors.
Regulation of osteocyte lifespan by mechanical signals.
A lack of mechanical stimulation, such as with immobi lization or paralysis, decreases bone mass and increases the risk of fractures. These effects are associated with the high prevalence of osteocyte apoptosis in mice and rats 100, 101 . Conversely, increasing levels of loading within the physiological range reduces the density of apoptotic osteocytes in rat ulnae 102 . The increase in osteocyte apoptosis with unloading might be due to the absence of survival signals provided by normal physical activity. Indeed, in vitro mechanical stimulation opposes the action of several proapoptotic Figure 5 | Osteocytic signalling pathways as therapeutic targets. Therapeutic approaches (pink lines and boxes) take advantage of osteocytic signalling pathways activated by mechanical and hormonal stimuli. The three main biological outcomes of these approaches are increased bone formation, decreased bone resorption and the promotion of osteocyte survival. Hormones and mechanical stimuli affect distinct but often overlapping signalling pathways that can be mimicked by pharmacological inhibitors or activators. Ab, antibody; DKK-1, Dickkopf-related protein 1; EP4, prostaglandin E 2 receptor EP4 subtype; ER, endoplasmic reticulum; ERα, oestrogen receptor α; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; Fc, fragment crystallizable region; JNK, c-Jun N-terminal kinase; OPG, osteoprotegerin; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A; PTH, parathyroid hormone; PTHrP, parathyroid hormone-related protein; PYK2, protein-tyrosine kinase 2β; RANK, receptor activator of nuclear factor-κB; RANKL, receptor activator of nuclear factor-κB ligand; ROS, reactive oxygen species; SFRP-1, secreted frizzled-related protein 1.
Glucocorticoids
Hormones secreted from the adrenal gland and used as immunomodulators that profoundly affect bone, decreasing bone mass and increasing the risk of fractures.
stimuli, and several mechanisms, in combination, are probably involved in promoting survival 103 . Integrin engagement and activation of focal adhesion kinase (FAK) are induced by mechanical stimulation, followed by activation of the Src-mitogenactivated protein kinase (MAPK)-extracellular signalregulated kinase (ERK) signalling cascade in vitro 104 . Furthermore, nuclear accumulation of the ERK survival kinase as well as ERKmediated gene transcription is required for an antiapoptotic effect. In in vivo studies, integrins have been found to be involved in the attachment of osteocytes to the lacunar-canalicular wall 105, 106 . Moreover, deletion of β1 integrin from osteocytes results in an abnormal response to unloading 107 , adding support to the hypoth esis of integrins having a role in mechanotransduction.
The canonical Wnt-βcatenin signalling pathway is also activated by loading 108 , in part due to decreased expression of antagonists of the pathway; that is, DKK1 and sclerostin 10, 108 . As Wnt proteins prevent apoptosis whereas Wnt antagonists (such as SFRP1 and sclerostin) induce apoptosis in cultured osteocytic and osteoblastic cells 68, 109, 110 , activation of this pathway could contribute to the maintenance of osteocyte and osteoblast survival with physiologic levels of loading. Furthermore, accu mulation of βcatenin, induced by mechanical stimula tion, is required for preventing glucocorticoidinduced osteocyte apoptosis in vitro 111, 112 , which suggests that canonical Wnt signalling also promotes survival under pathological conditions. Moreover, in vivo activation of Wnt-βcatenin signalling, as in mice lacking the Wnt antagonist SFRP1(REF. 65) or those expressing LRP5 activating mutations 113 , leads to a reduction in apop totic osteocytes. Mechanical stimulation of osteocytes also induces the release of PGE 2 , produced by cyclo oxygenase 2, an enzyme induced by mechanical stimu lation 114 . Binding of PGE 2 to prostaglandin E2 receptor EP2 subtype (EP2) and subsequent activation of the cAMP-protein kinase A (PKA) and phosphoinositide 3kinase (PI3K)-protein kinase B (AKT)-βcatenin pathways inhibits apoptosis of osteocytic cells induced by glucocorticoids 112 . Some of these prosurvival pathways activated by loading in osteocytes are also required for the anabolic effect induced by mechanical stimulation. Mice lack ing the Wnt coreceptor LRP5 or overexpressing Sost, thus, do not exhibit an anabolic response to loading 11, 115 , and inhibition of prostaglandin synthesis blocks bone formation induced by mechanical stimulation 116 .
Crosstalk between mechanical and hormonal signals in osteocytes. One example of a prosurvival pathway activated by mechanical stimuli that is also involved in hormonal responses is tyrosine kinase Src-ERK signal ling, which is activated by mechanical stimulation down stream of integrins and FAK and by oestrogens and/or androgens via nongenotropic signalling that are medi ated by extranuclear functions of the oestrogen receptor (ER) or androgen receptor 104, 117 (FIG. 5) . ERα or ERβ also have a permissive role in mechanotransduction, as their presence in the osteocytic cell membrane within cav eolae is required for the ERKmediated survival effect of mechanical stimulation in a ligandindependent fashion 118 . Additionally, oestrogen as well as mechanical stimulation induce ERα phosphorylation in an ERK dependent and PKAdependent manner 119 . Consistent with these in vitro findings, mice lacking ERα or ERβ exhibit a reduced anabolic response to loading 120, 121 . Similar to mechanical stimulation, systemic elevation of PTH levels reduces the expression of SOST and scleros tin, which might contribute to the increase in bone forma tion mediated by this hormone 2, 122 . Consistent with this notion, the increase in bone mass and bone formation in transgenic mice expressing an activated PTH receptor in osteocytes is abrogated by Sost overexpression 14 . Moreover, PTH signalling might interact with mechano transduction pathways, as the anabolic response to mechanical stimula tion is enhanced when PTH is administered together with loading [123] [124] [125] [126] and is decreased in parathyroidectomized rats 123 . In addition, the increase in cancellous bone vol ume and improvement in mechanical properties induced by exercise are abolished when activation of PTH receptor is inhibited by PTH in mice 127 . The effect of PTH in combination with mechanical stimulation is blocked by verapamil 128 , which suggests the involvement of Ltype voltage channels in the synergistic effect between the hormone and loading.
The PTH receptor can also be activated by the binding of PTHrP. Levels of PTHrP are increased by mechanical stimulation in osteocytic and osteoblastic cells 129, 130 , and the antiapoptotic effect of mechanical stimulation is mimicked by treatment with PTHrP and abolished by silencing Pth1r in vitro 130, 131 . PTHrP, similar to PTH, decreases Sost expression in primary cultures of osteo blastic cells containing osteocytes 15 . Taken together, this evidence strongly suggests that local increases in PTHrP induced by mechanical loading could contribute to maintaining osteocyte survival and the anabolic action of mechanical loading.
In contrast to the overlapping and potentially syner gistic signalling activated by mechanical signals, sex steroids or PTH, glucocorticoids antagonize survival and bonemaintaining signalling activated by mechanical stimulation. Glucocorticoids induce osteocyte and osteo blast apoptosis in vitro and in vivo in mice and humans, thus opposing the survival effect of mechanical stimuli on these cells 103, [132] [133] [134] [135] [136] . Whereas glucocorticoids inhibit, mechanical stimulation promotes Wnt-βcatenin sig nalling. Furthermore, whereas mechanical stimulation activates the FAK-ERK survival pathway, glucocorti coidinduced apoptosis is preceded by cell detachment (known as anoikis) through the activation of FAKrelated kinase, proteintyrosine kinase 2β (PYK2), and cJun Nterminal kinase 104, 137 . The finding that glucocorticoids oppose the FAK-ERK pathway through activation of PYK2 raises the possibility that inhibition of this pro tein could increase mechanoresponsive FAK signalling. Indeed, a PYK2 inhibitor can increase bone mass in rodents through stimulation of bone formation and inhi bition of bone resorption 138, 139 . Additionally, some of the proapoptotic actions of glucocorticoids on osteocytes and osteoblasts are mediated by endoplasmic reticu lum stress; inhibition of phosphorylation of eukaryotic translation initiation factor 2α, which leads to endoplasmic reticulum stress, prevents apoptosis and the loss of bone mass induced by glucocorticoid excess in mice 140 . Increased levels of endogenous glucocorticoids might contribute to the effect of reduced mechanical stimulation, as evidenced by a delayed increase in osteoblast apoptosis and a reduction in serum levels of osteocalcin and ver tebral strength in mice expressing the gluco corticoid inactivating enzyme 11β hydroxy steroid dehydrogenase in osteoblastic cells (designated OG211β HSD2 mice) and subjected to tail suspension 100 . Conversely, osteo cytes still exhibit apoptosis in tailsuspended OG211β HSD2 mice, which indicates that the effect of unloading on osteocytes is not a consequence of increased endoge nous glucocorticoids, but is entirely caused by reduced mechanical loading.
Targeting osteocytic signalling pathways Our increased understanding of the mechanosensory pathways provides opportunities for developing ther apeutic approaches to improve bone health (FIG. 5) . Agents that prevent osteocyte apoptosis preserve bone strength 141 . Such is the case with bisphosphonates, as their antifracture efficacy cannot be completely explained by the effect of the drugs on bone mass. Bisphosphonates prevent osteocyte apoptosis induced by glucocorticoid excess and lack of mechanical forces; this effect does not require the anticatabolic activity of the drugs, as it is exerted by bisphosphonate ana logues that inhibit apoptosis of osteoblastic cells with out affecting osteoclast function 98, 133, 142 . Oestrogens and androgens have also been shown to preserve osteocyte viability, and removal of sex steroids increases osteocyte apoptosis 117, 143 . In addition, intermittent administration of PTH decreases osteocyte apoptosis and increases osteocyte density 144, 145 . Activation of Wnt-βcatenin signalling either by blocking inhibitors of the pathway directly or through mechanical stimulation, or as a con sequence of PTH administration, promotes osteocyte survival 112, 122, 146, 147 . Furthermore, inhibition of osteocyte apoptosis with caspase inhibitors decreases resorption following fatigue loading or ovariectomyinduced thin ning of cortical bone 96 , and prevents the increase in bone resorption and loss of bone induced by immobilization of the appendicular skeleton 99 . These pieces of evidence support the possibility that by preventing osteocyte (and osteoblast) apoptosis, bone mass can be maintained and the effect of deleterious stimuli on bone can at least, in part, be neutralized.
Several ways of activating Wnt-βcatenin signalling by blocking antagonists of the pathway through phar macological interventions have been designed. Studies using humanized neutralizing antiDKK1 antibodies increase bone mass in growing female mice and in ovari ectomized adult rhesus monkeys 148, 149 . In addition, a small molecule inhibitor of SFRP1 increases bone vol ume in calvaria organ cultures 150 . Furthermore, inhibition of glycogen synthase3β, which stabilizes βcatenin and activates canonical Wnt signalling, protects bone integ rity, as shown in preclinical studies as well as in epide miological studies in which the glycogen synthase3β inhibitor, lithium chloride, was used to treat psychological disorders 65 . However, since the Wnt pathway is active in numerous tissues and both DKK1 and SFRP1 are widely expressed, use of these inhibitors might need to be restricted to local bone applications to avoid unwanted effects in other organs. Nevertheless, antiDKK1 anti bodies are currently being tested for the treatment of skeletal complications in multiple myeloma 151 . A neutralizing antibody directed against scleros tin has also been developed. Sclerostin expression is restricted to osteocytes among bone cells and increased SOST expression leads to a bonespecific phenotype. Sclerostin is, therefore, an excellent target to improve bone health without affecting other tissues. Preclinical studies have shown that inhibition of sclerostin using the antibody prevents the decrease in bone mass induced by ovariectomy, excess glucocorticoid administration, ulcerative colitis, immobilization and ageing 152 . Phase II studies with the antisclerostin antibody have been carried out in postmenopausal women and increased BMD, increased bone formation and inhibition of bone resorption reported 153 . Sclerostin has also been detected in chondro cytes [154] [155] [156] , which raises the possibility that treatment with the antisclerostin antibody can affect cartilage. In fact, deletion of Sost in mice worsens the osteoarthritic phenotype induced by medial meniscus destabiliza tion 157 . However, no difference in the development of agedependent osteoarthritis was found between wild type and Sost knockout mice 156 . Moreover, intraarticular administration of an antisclerostin antibody did not alter the osteoarthritic phenotype induced by medial meniscus destabilization in rats 156 , and no adverse osteo arthritic events have been reported in human trials with antisclerostin antibodies 158 . Overall, these studies sug gest that even when sclerostin is expressed in cartilage, neutralization of its activity might not significantly affect the functionality of this tissue.
Studies have shown that administration of an inacti vating FGF23 antibody reverses hypophosphataemia and increases levels of 1,25dihydroxyvitamin D in patients with Xlinked hypophosphataemic rickets 159 . The anti body also increases circulating markers of bone formation, which suggests an improvement in bone mineralization. Consistent with this possibility, administration of the antiFGF23 antibody improved mineralization in adult hyp mice, a model of Xlinked hypophosphataemic rick ets 160 . Furthermore, a panspecific FGF receptor inhibitor reversed abnormal serum levels of phosphate, calcium, PTH and 1,25dihydroxyvitamin D, and improved the skeletal manifestations of hypophosphataemia in hyp mice, as well as in mice lacking DMP1, a model of autosomal recessive hypophosphataemic rickets 161 . Attempts have been made over the years to block osteoclast differentiation and, therefore, to reduce bone loss by targeting the RANKL-RANK-OPG signalling pathway [162] [163] [164] . As current evidence suggest that osteo cytes are one of the sources of RANKL and OPG in bone, therapeutic approaches that modulate this pathway are examples of the potential benefits of targeting osteocytes to improve skeletal health. PGE 2 has an anabolic effect in bone when administered intermittently 165 . However, owing to the widespread systemic distribution and the adverse effects associated with PGE 2 administration, this agent is not currently used in the clinic. PGE 2 acts in bone via activation of EP2 and EP4 receptors. Deletion of the gene encod ing EP4 results in osteopenia in mice, with increased osteoclast numbers and decreased bone formation 166 . Agonists of EP4 have been developed and can stim ulate bone formation and inhibit bone resorption in ovariectomized rats 167 . To avoid the systemic effects of activation of this receptor, a bisphosphonateconjugated agonist was developed for bone targeting 168 . The EP4 agonist-bisphosphonate conjugate increased bone for mation and improved bone strength in ovariectomized rats 168 . Levels of EP2, the other PGE 2 receptor expressed in bone, are increased by mechanical stimulation and are involved in the effects of PGE 2 on osteocytic cells upon mechanical stimulation in vitro 41 . Furthermore, deletion of the gene encoding EP2 in mice impairs osteoclastogenesis and decreases bone strength 169 . Agonists of EP2 have been developed and induce peri osteal bone formation upon local administration in rats. Whether activation of this receptor in osteocytes con tributes to the effects of EP agonists remains unknown.
Conclusions
Over the past two decades, our understanding of the func tion of osteocytes both as regulators of the activity of bone forming and resorbing cells, and as modulators in other tissues, has markedly increased. Human mutations and experimental models have uncovered novel signalling pathways activated in osteocytes that can be targeted with therapeutic agents to improve bone health. Furthermore, some stimuli that affect osteocytes and other bone cells also affect skeletal muscle and vice versa. In particular, mechan ical stimulation is required for maintaining both bone and muscle homeostasis. Crosstalk between these two tissues might be exploited in the future to develop agents that treat the musculoskeletal system as a single entity.
